Combined therapy with co-amoxiclav and erythromycin against intracellular Legionella pneumophila in cell culture and in an experimental respiratory infection in neutropenic rats.
Smith
G M
GM
SmithKline Beecham Pharmaceuticals, Surrey, UK.
Abbott
K H
KH
Beale
A S
AS
D000658:Amoxicillin / Q000494:pharmacology / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D000818:Animals; D002478:Cells, Cultured; D002969:Clavulanic Acids / Q000494:pharmacology / Q000627:therapeutic use; D003520:Cyclophosphamide; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use*; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use*; D005347:Fibroblasts; D006801:Humans; D016952:Legionella pneumophila / Q000187:drug effects*; D007877:Legionnaires' Disease / Q000188:drug therapy* / Q000382:microbiology; D008168:Lung / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications* / Q000382:microbiology; D051381:Rats
D002969:Clavulanic Acids; D004917:Erythromycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D003520:Cyclophosphamide